#173
PDF
IF 5.52
Expert consensus on the use of omalizumab in chronic urticaria in China
Bibliographic Details
- Authors
- Corresponding Author(s) +
- Zhao, Z., Maurer, M.
- Journal / Publisher
- World Allergy Organ. J
- Publication Date
- 2021
- Volume / Edition
- 14
- Pages
- e100610
- Impact Factor
- 5.52
Citation
Zhao, Z., Cai, T., Chen, H., Chen, L., Chen, Y., Gao, X., Gao, X., Geng, S., Guo, Y., Hao, F., Hao, G., Hu, Y., Jin, H., Jin, Z., Li, C., Li, H., Li, J., Li, Y., Liang, Y., Liu, G., Liu, Q., Long, H., Ma, L., Shang, Y., Song, Y., Song, Z., Su, X., Sui, H., Sun, Q., Sun, Y., Tang, J., Tong, X., Wang, H., Wang, G., Wang, L., Wang, S., Xiang, L., Xiao, T., Xie, Z., Ye, L., Yu, Y., Zhang, C., Zhang, L., Zhang, S., Zheng, R., Zhi, L., Zhou, W., Zou, Y., Maurer, M.: Expert consensus on the use of omalizumab in chronic urticaria in China. World Allergy Organ. J 2021: 14; e100610. IF: 5.52